HRP20170263T1 - LIJEČENJE ARTERIJSKE STJENKE KOMBINACIOJM RAAS INHIBITORA I HMG-CoA REDUKTAZE - Google Patents

LIJEČENJE ARTERIJSKE STJENKE KOMBINACIOJM RAAS INHIBITORA I HMG-CoA REDUKTAZE

Info

Publication number
HRP20170263T1
HRP20170263T1 HRP20170263TT HRP20170263T HRP20170263T1 HR P20170263 T1 HRP20170263 T1 HR P20170263T1 HR P20170263T T HRP20170263T T HR P20170263TT HR P20170263 T HRP20170263 T HR P20170263T HR P20170263 T1 HRP20170263 T1 HR P20170263T1
Authority
HR
Croatia
Prior art keywords
inhibitor
hmg
treatment
combination
coa reductase
Prior art date
Application number
HRP20170263TT
Other languages
English (en)
Inventor
Miso Sabovic
Original Assignee
Ims Medical D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ims Medical D.O.O. filed Critical Ims Medical D.O.O.
Publication of HRP20170263T1 publication Critical patent/HRP20170263T1/hr
Publication of HRP20170263T2 publication Critical patent/HRP20170263T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20170263TT 2011-12-09 2017-02-20 LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE HRP20170263T2 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SI201100459 2011-12-09
SI201200268 2012-08-27
PCT/EP2012/005074 WO2013083286A1 (en) 2011-12-09 2012-12-07 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
EP12798615.6A EP2787993B1 (en) 2011-12-09 2012-12-07 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR

Publications (2)

Publication Number Publication Date
HRP20170263T1 true HRP20170263T1 (hr) 2017-04-21
HRP20170263T2 HRP20170263T2 (hr) 2018-12-28

Family

ID=47326055

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170263TT HRP20170263T2 (hr) 2011-12-09 2017-02-20 LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE

Country Status (6)

Country Link
US (1) US9498464B2 (hr)
EP (1) EP2787993B1 (hr)
ES (1) ES2622893T3 (hr)
HR (1) HRP20170263T2 (hr)
SI (1) SI2787993T1 (hr)
WO (1) WO2013083286A1 (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064191A2 (en) * 2012-10-24 2014-05-01 Biocopea Limited Drug combinations and uses
EP2923698B1 (en) * 2012-11-23 2021-04-28 Peking University Third Hospital Statin compound for use in treating obesity, hypertension and hyperlipaemia by intraosseous administration
EP3290022B1 (en) * 2016-09-01 2020-04-01 Peking University Third Hospital Use of statins in the treatment of ischemic diseases
EP3963602A1 (en) * 2019-05-02 2022-03-09 Closed Loop Medicine Ltd Methods and systems for providing personalised medicine to a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
KR20050092119A (ko) * 2003-01-16 2005-09-20 베링거 인겔하임 인터내셔날 게엠베하 심혈관 질환, 심폐 질환, 폐 질환 또는 신장 질환을예방하거나 치료하기 위한 약제학적 배합물
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20090023691A1 (en) 2005-04-07 2009-01-22 Miso Sabovic Delaying the ageing process and disorders caused by ageing
KR100985254B1 (ko) * 2006-10-30 2010-10-04 한올바이오파마주식회사 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와ＨＭＧ―ＣｏＡ 환원 효소 억제제의 복합 조성물
KR101238156B1 (ko) * 2008-04-29 2013-02-27 한올바이오파마주식회사 약제학적 제제
US20130338203A1 (en) 2011-02-28 2013-12-19 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR

Also Published As

Publication number Publication date
HRP20170263T2 (hr) 2018-12-28
WO2013083286A1 (en) 2013-06-13
ES2622893T3 (es) 2017-07-07
SI2787993T1 (sl) 2017-04-26
US20140323536A1 (en) 2014-10-30
EP2787993A1 (en) 2014-10-15
EP2787993B1 (en) 2016-11-23
US9498464B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
AP3576A (en) Inhibitors of flaviviridae viruses
IL220956A (en) Inhibitors of s-nitrosoglutathione reductase
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1171443A1 (en) Inhibitors of flaviviridae viruses
EP2588474A4 (en) PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF
ZA201206456B (en) Uses of dgati inhibitors
WO2012092202A9 (en) Modulation of side effect profile of 5-alpha reductase inhibitor therapy
ZA201208363B (en) Novel intermediates for the preparation of hmg-coa reductase inhibitors
IL257069B (en) Inhibitors of cell death and uses thereof
IL228719A0 (en) parp inhibitors for the treatment of cipn
HRP20170263T2 (hr) LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE
EP2533637A4 (en) CHROMINIA S-NITROSOGLUTATHION REDUCTASE
GB201103293D0 (en) Treatment and prevention of malaria
WO2012109065A9 (en) Treatment and prevention of cardiovascular disease and thrombosis
IL237425A0 (en) Composite capsule pharmaceutical preparation containing irbesartan and HMG coa reductase inhibitor and methods for its production
RS56682B1 (sr) Postupci primene egfr inhibitora
AU2010903897A0 (en) Method of mental diseases prevention
AU2012904868A0 (en) Treatment or Prevention of Cardiovascular Events
AU2011902491A0 (en) Prevention and treatment of haematological conditions
AU2010905095A0 (en) Surface Treatment of Metal Objects
GB0911084D0 (en) New use of statins
AU2010901680A0 (en) Treatment of metals